




*Imape*

1723



Docket No.: 9350-0136-0

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

ATTORNEYS AT LAW

NORMAN F. OBLON  
(703) 413-3000  
NOBLON@OBLON.COM

JAMES J. KELLY  
(703) 413-3000  
JKELLY@OBLON.COM

RE: Application Serial No.: 09/399,743  
Applicants: Karlheinz DRUZ, et al.  
Filing Date: September 20, 1999  
For: AMINO ACID COMPOSITION FOR  
HEMODIALYSIS  
Group Art Unit: 1723  
Examiner: S.U. KIM

SIR:


Attached hereto for filing are the following papers:

**Request for Reconsideration w/Attachments**

Our check in the amount of **\$0.00** is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

  
Norman F. Oblon  
Registration No. 24,618

Customer Number

**22850**

(703) 413-3000 (phone)  
(703) 413-2220 (fax)

James J. Kelly  
Registration No. 41,504



DOCKET NO: 9350-0136-0

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :  
KARLHEINZ DRUZ, ET AL. : EXAMINER: S.U. KIM  
SERIAL NO: 09/399,743 :  
FILED: SEPTEMBER 20, 1999 : GROUP ART UNIT: 1723  
FOR: AMINO ACID COMPOSITION FOR HEMODIALYSIS

REQUEST FOR RECONSIDERATION

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Office Action dated March 8, 2004, Applicants respectfully request reconsideration of the above-identified application in view of (a) the executed Declaration submitted on June 24, 2003, (b) the English translations submitted on August 25, 2003, and (c) the following remarks.

The **Remarks** begin on page 2 of this paper.